A 13-year-old boy, who suffered multiple life-threatening injuries after falling from the fifth floor of a building in Hyderabad, recovered after 34 days of intensive treatment at Rainbow Hospitals.
Trutakna, priced at $425,000 per year, is the first drug approved in the U.S. that targets both BAFF and APRIL proteins ...
FDA grants accelerated approval to Vera's Trutakna for IgA nephropathy, first dual BAFF/APRIL inhibitor. Competes with ...
Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgA nephropathy (IgAN) that will compete with ...
Longevity medicine relies on advanced biomarker analysis to support preventive healthcare and more personalized patient ...
Finerenone shows promise in slowing chronic kidney disease progression in non-diabetic patients, according to recent global ...
TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA ...
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...
A surprising finding has revealed that the kidneys may control water retention through an additional pathway beyond the one ...
WHEN should you take sunburn seriously, especially in small children? As a GP, I think parents and grandparents worry about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results